Genetic association in CYP3A4 and CYP3A5 genes elevate the risk of prostate cancer

References

• Bangsi D, Zhou J, Sun Y, Patel NP, Darga LL, Heilbrun LK, Powell IJ, Severson RK, et al. 2006. Impact of a genetic variant in CYP3A4 on risk and clinical presentation of prostate cancer among white and African–American men. Urol Oncol. 24(1):21–27.
   PubMed Web of Science ®Google Scholar
• Bellah F, Salam A, Billah SMS, Karim R. 2022. Genome-wide association study of CYP3A4 and CYP3A5 genes in relation to the risk of Prostate Cancer among Bangladeshi population. PREPRINT (Version 1) available at Research Square.
   Google Scholar
• Bray F, Kiemeney L. 2017. Epidemiology of prostate cancer in Europe: patterns, trends and determinants. In: Bolla M, van Poppel H, editors. Management of prostate cancer: a multidisciplinary approach. Berlin: Springer-Verlag; p. 1–11.
   Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. 2018. Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK, Varambally S. 2017. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 19(8):649–658.
   PubMed Web of Science ®Google Scholar
• Chou KC. 2015. Impacts of bioinformatics to medicinal chemistry. Med Chem. 11(3):218–234.
   PubMed Web of Science ®Google Scholar
• Emoto C, Iwasaki K. 2006. Enzymatic characteristics of CYP3A5 and CYP3A4: a comparison of in vitro kinetic and drug-drug interaction patterns. Xenobiotica. 36(2–3):219–233.
   PubMed Web of Science ®Google Scholar
• Fernandez P, Zeigler-Johnson CM, Spangler E, van der Merwe A, Jalloh M, Gueye SM, Rebbeck TR. 2012. Androgen metabolism gene polymorphisms, associations with prostate cancer risk and pathological characteristics: a comparative analysis between South African and Senegalese men. Prostate Cancer. 2012:798634.
   PubMedGoogle Scholar
• Islam MS, Ahmed MU, Sayeed MSB, Maruf AA, Mostofa AGM, Hussain SMA, Kabir Y, Daly AK, et al. 2013. Lung cancer risk in relation to nicotinic acetylcholine receptor, CYP2A6 and CYP1A1 genotypes in the Bangladeshi population. Clin Chim Acta. 416:11–19.
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. 2011. Global cancer statistics. CA Cancer J Clin. 61(2):69–90.
   PubMed Web of Science ®Google Scholar
• Kedishvili NY. 2016. Retinoic acid synthesis and degradation. In: The biochemistry of retinoid signaling II. Berlin: Springer; p. 127–161.
   Google Scholar
• Kreutz R, Zuurman M, Kain S, Bolbrinker J, de Jong PE, Navis G. 2005. The role of the cytochrome P450 3A5 enzyme for blood pressure regulation in the general Caucasian population. Pharmacogenet Genomics. 15(12):831–837.
   PubMed Web of Science ®Google Scholar
• Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, et al. 2001. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 27(4):383–391.
   PubMed Web of Science ®Google Scholar
• Leskelä S, Honrado E, Montero-Conde C, Landa I, Cascón A, Letón R, Talavera P, Cózar JM, et al. 2007. Cytochrome P450 3A5 is highly expressed in normal prostate cells but absent in prostate cancer. Endocr Relat Cancer. 14(3):645–654.
   PubMed Web of Science ®Google Scholar
• Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, Li B, Liu XS. 2020. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 48:W509–W514.
   PubMed Web of Science ®Google Scholar
• Nogal A, Coelho A, Catarino R, Morais A, Lobo F, Medeiros R. 2007. The CYP3A4*1B polymorphism and prostate cancer susceptibility in a Portuguese population. Cancer Genet Cytogenet. 177(2):149–152.
   PubMedGoogle Scholar
• Paris PL, Kupelian PA, Hall JM, Williams TL, Levin H, Klein EA, Casey G, Witte JS. 1999. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol Biomark Prev. 8:901–905.
   PubMed Web of Science ®Google Scholar
• Plummer SJ, Conti DV, Paris PL, Curran AP, Casey G, Witte JS. 2003. CYP3A4 and CYP3A4 genotypes, haplotypes, and risk of prostate cancer. Cancer Epidemiol Biomark Prev. 12:928–932.
   PubMed Web of Science ®Google Scholar
• Rais N, Chawla YK, Kohli KK. 2006. CYP3A phenotypes and genotypes in North Indians. Eur J Clin Pharmacol. 62(6):417–422.
   PubMed Web of Science ®Google Scholar
• Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB. 1998. Modification of clinical presentation of prostate tumors by a novel genetic variantin CYP3A4. J Natl Cancer Inst. 90(16):1225–1229.
   PubMed Web of Science ®Google Scholar
• Sailaja K, Rao DN, Rao DR, Vishnupriya S. 2010. Analysis of CYP3A5*3 and CYP3A5*6 gene polymorphisms in Indian chronic myeloid leukemia patients. Asian Pac J Cancer Prev. 11(3):781–784.
   PubMedGoogle Scholar
• Salameh G, Hadidi KA, Khateeb ME. 2012. Genetic polymorphisms of the CYP3A4, CYP3A5, CYP3A7 and CYP1A2 among the Jordanian population. Environ Toxicol Pharmacol. 34(1):23–33.
   PubMed Web of Science ®Google Scholar
• Spurdle AB, Goodwin B, Hodgson E, Hopper JL, Chen X, Purdie DM, McCredie MR, Giles GG, et al. 2002. The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. Pharmacogenetics. 12:355–366.
   PubMedGoogle Scholar
• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. 2021. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. 2017. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45(W1):W98–W102.
   PubMed Web of Science ®Google Scholar
• Tayeb MT, Clark C, Sharp L, Haites NE, Rooney PH, Murray GI, Payne SN, McLeod HL. 2002. CYP3A4CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia. Oncol Rep. 9(3):653–655.
   PubMed Web of Science ®Google Scholar
• Thummel KE, O’Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, Wilkinson GR. 1996. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther. 59(5):491–502.
   PubMed Web of Science ®Google Scholar
• Van Schaik RH. 2005. Cancer treatment and pharmacogenetics of cytochrome P450 enzymes. Invest New Drugs. 23(6):513–522.
   PubMed Web of Science ®Google Scholar
• Walker AH, Jaffe JM, Gunasegaram S, Cummings SA, Huang CS, Chern HD, Olopade OI, Weber BL, et al. 1998. Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Hum Mutat. 12(4):289.
   PubMedGoogle Scholar
• Westlind A, Löfberg L, Tindberg N, Andersson TB, Ingelman-Sundberg M. 1999. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region. Biochem Biophys Res Commun. 259(1):201–205.
   PubMed Web of Science ®Google Scholar
• World Medical Association. 2013. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 310(20):2191–2194.
   PubMed Web of Science ®Google Scholar
• Wrighton SA, Stevens JC. 1992. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol. 22(1):1–21.
   PubMed Web of Science ®Google Scholar
• Xu Y, Chou KC. 2016. Recent progress in predicting posttranslational modification sites in proteins. Curr Top Med Chem. 16(6):591–603.
   PubMed Web of Science ®Google Scholar
• Zeigler-Johnson C, Friebel T, Walker AH, Wang Y, Spangler E, Panossian S, Patacsil M, Aplenc R, et al. 2004. CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer. Cancer Res. 64(22):8461–8467.
   PubMed Web of Science ®Google Scholar
• Zhenhua L, Tsuchiya N, Narita S, Inoue T, Horikawa Y, Kakinuma H, Kato T, Ogawa O, et al. 2005. CYP3A5 gene polymorphism and risk of prostate cancer in a Japanese population. Cancer Lett. 225(2):237–243.
   PubMed Web of Science ®Google Scholar